BioSpace News Archive

Black Diamond Therapeutics, Inc. announced that company management will participate in three upcoming investor conferences:

Cue Biopharma, Inc. announced that it will present at two investor conferences this November, the Stifel Healthcare Conference 2022, to be held November 15-16 in New York, and the Jefferies London Healthcare Conference, to be held in London, UK, November 15-17.

Cogent Biosciences, Inc. announced that management will participate in the following upcoming investor conferences:

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:50 p.m. ET.

CinCor Pharma, Inc. announced that company management will participate at the Jefferies London Healthcare Conference taking place on November 15-17, 2022 in London, United Kingdom.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication in the journal CHEST of positive results from a Phase 1b/2a randomized, double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease.

RAPT Therapeutics, Inc. today announced that members of the RAPT management team will participate in the following investor conferences in November.

Lyra Therapeutics, Inc. announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the following investor conferences in November.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents (numbers 7160345 and 10-2441425) entitled “Combined Preparations for the Treatment of Cancer” by the Japanese Patent Office and South Korean Patent Office, respectively.

Lipocine Inc. today announced financial results for the third quarter and nine months ended September 30, 2022 and provided a corporate update.